SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today ...
(NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that Alfred Hospital is now ...
Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with ...
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today ...
Wednesday, Oragenics Inc. (NYSE:OGEN) announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion. Oragenics is a ...
Oragenics closed a public offering, raising $16.5 million for its concussion drug development and general corporate purposes. Oragenics, Inc., a biotechnology company specializing in intranasal ...
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today ...
Oragenics plans to offer 800,000 shares of preferred stock and warrants, aiming to raise $20 million for clinical trials and operations. Oragenics, Inc. announced that it has entered into an agreement ...
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San ...
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, ...
SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has ...
ALACHUA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. today announced that Stanley B. Stein resigned as President, Chief Executive Officer and director of Oragenics, Inc.(the "Company"), effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results